Advancing novel treatments for dry eye and ocular surgery

Kala Pharmaceuticals (NASDAQ: KALA) is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, with an initial focus on the treatment of eye diseases. Kala has applied the MPP technology to a corticosteroid designed for ocular applications, resulting in two lead product candidates. The product candidates are INVELTYSTM (KPI-121 1%) for the treatment of inflammation and pain following ocular surgery, for which we have submitted a NDA, and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease, which is currently in Phase 3 clinical development.

Year Invested: 2009
Location: Waltham, Mass.

Recent News

March 14, 2018
Kala Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare Conference

March 5, 2018
Kala Pharmaceuticals Appoints Gregory Perry to Board of Directors and as Audit Committee Chair

January 5, 2018
Kala Pharmaceuticals Announces Topline Results for Two Phase 3 Trials (STRIDE 1 and STRIDE 2) of KPI-121 0.25% in Dry Eye Disease

Read More News

Associated Team Members

Robert Tepper, M.D.